tetano
Editor, Senior Moderator
Jpn J Infect Dis
. 2024 Apr 30.
doi: 10.7883/yoken.JJID.2024.011. Online ahead of print. Anti-SARS-CoV-2 nucleocapsid antibody positivity 3 years after COVID-19
Chang Kyung Kang[SUP] 1 [/SUP], Youngju Kim[SUP] 2 3 [/SUP], Hyeon Jae Jo[SUP] 1 [/SUP], Chan Mi Lee[SUP] 1 [/SUP], Nam Joong Kim[SUP] 1 [/SUP], Chang-Han Lee[SUP] 2 3 4 5 6 [/SUP], Pyoeng Gyun Choe[SUP] 1 [/SUP], Wan Beom Park[SUP] 1 [/SUP], Myoung-Don Oh[SUP] 1 [/SUP]
Affiliations
The accurate identification of individuals without prior infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pivotal for seroepidemiological research and vaccine trials. Because of widespread COVID-19 vaccination, the anti-nucleocapsid antibody continues to serve as a valuable marker for individuals without a history of COVID-19. This study aimed to comprehensively assess anti-nucleocapsid antibody positivity using diverse commercial and in-house immunoassays among individuals who contracted COVID-19 more than 3 years ago. We enrolled 44 participants with laboratory-confirmed COVID-19 between January and May 2020 from Seoul National University Hospital and its community treatment centers. The results showed anti-nucleocapsid antibody positivities ranged from 45.5% to 87.9% depending upon the immunoassay used. The study highlights the importance of considering the limited anti-nucleocapsid antibody positivity in participants with a distant COVID-19 history in seroepidemiological or vaccine research.
Keywords: 3 years; COVID-19; SARS-CoV-2; anti-nucleocapsid antibody; positivity.
. 2024 Apr 30.
doi: 10.7883/yoken.JJID.2024.011. Online ahead of print. Anti-SARS-CoV-2 nucleocapsid antibody positivity 3 years after COVID-19
Chang Kyung Kang[SUP] 1 [/SUP], Youngju Kim[SUP] 2 3 [/SUP], Hyeon Jae Jo[SUP] 1 [/SUP], Chan Mi Lee[SUP] 1 [/SUP], Nam Joong Kim[SUP] 1 [/SUP], Chang-Han Lee[SUP] 2 3 4 5 6 [/SUP], Pyoeng Gyun Choe[SUP] 1 [/SUP], Wan Beom Park[SUP] 1 [/SUP], Myoung-Don Oh[SUP] 1 [/SUP]
Affiliations
- PMID: 38684427
- DOI: 10.7883/yoken.JJID.2024.011
The accurate identification of individuals without prior infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pivotal for seroepidemiological research and vaccine trials. Because of widespread COVID-19 vaccination, the anti-nucleocapsid antibody continues to serve as a valuable marker for individuals without a history of COVID-19. This study aimed to comprehensively assess anti-nucleocapsid antibody positivity using diverse commercial and in-house immunoassays among individuals who contracted COVID-19 more than 3 years ago. We enrolled 44 participants with laboratory-confirmed COVID-19 between January and May 2020 from Seoul National University Hospital and its community treatment centers. The results showed anti-nucleocapsid antibody positivities ranged from 45.5% to 87.9% depending upon the immunoassay used. The study highlights the importance of considering the limited anti-nucleocapsid antibody positivity in participants with a distant COVID-19 history in seroepidemiological or vaccine research.
Keywords: 3 years; COVID-19; SARS-CoV-2; anti-nucleocapsid antibody; positivity.